SEC Comment Letter 0000000000-26-001911 to Benitec Biopharma Inc. (BNTC)
Benitec Biopharma Inc.
Date: Feb. 24, 2026 · CIK: 0001808898 · Accession: 0000000000-26-001911
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-39267
Letter
February 24, 2026 Megan Boston Chief Financial Officer Benitec Biopharma Inc. 3940 Trust Way Hayward, California 94545 Re:Benitec Biopharma Inc. Form 10-K for Fiscal Year Ended June 30, 2025 File No. 001-39267 Dear Megan Boston: We have limited our review of your filing to the financial statements and related disclosures and have the following comment. Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments. Form 10-K for Fiscal Year Ended June 30, 2025 Report of Independent Registered Public Accounting Firm, page F-2 1.We note the signature of Baker Tilly US, LLP has been omitted from their audit report. Please amend your filing to provide a signed audit report. Refer to Rule 2-02(a)(2) of Regulation S-X.
In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
February 24, 2026 Page 2 Please contact Eric Atallah at 202-551-3663 or Lynn Dicker at 202-551-3616 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
February 24, 2026
Megan Boston
Chief Financial Officer
Benitec Biopharma Inc.
3940 Trust Way
Hayward, California 94545
Re:Benitec Biopharma Inc.
Form 10-K for Fiscal Year Ended June 30, 2025
File No. 001-39267
Dear Megan Boston:
We have limited our review of your filing to the financial statements and related
disclosures and have the following comment.
Please respond to this letter within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe a
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this letter, we may have additional comments.
Form 10-K for Fiscal Year Ended June 30, 2025
Report of Independent Registered Public Accounting Firm, page F-2
1.We note the signature of Baker Tilly US, LLP has been omitted from their audit report.
Please amend your filing to provide a signed audit report. Refer to Rule 2-02(a)(2) of
Regulation S-X.
In closing, we remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
February 24, 2026
Page 2
Please contact Eric Atallah at 202-551-3663 or Lynn Dicker at 202-551-3616 with any
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences